Freenome, Inc.

Freenome, Inc., trading under the ticker PCSC, filed a Form S-1 registration statement with the Securities and Exchange Commission on August 18, 2026, accession number 0001140361-26-033585, marking a significant step in its path to public markets. The company operates in the precision-oncology diagnostics sector, with its platform centered on multi-cancer early detection through blood-based screening. The S-1 is currently under SEC review, and the offering has not yet been declared effective as of the filing date. Freenome has attracted substantial backing from life-sciences investors during its private years, positioning it among the more closely watched diagnostics names entering the public arena. For the complete filing breakdown, cap-table data, and real-time status updates on PCSC, sign up for full access at SpacDesk.